AbbVievsCullinan Therapeutics

ABBV and CGEM stock compared: price, dividend, valuation and results, from SEC filings.

CGEM

Cullinan Therapeutics, Inc.

$8.89

Value $577M

-1.98%
CGEM's page

AbbVie (ABBV) has a market value of $506B and Cullinan Therapeutics (CGEM) $577M. Over the last year, with dividends, ABBV moved +26.6% and CGEM +5.2%. Dividend yield: ABBV 2.42%, CGEM none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$506B

    CGEM$577M

    ABBV is 877 times CGEM

  • Revenue, 12 months

    ABBV$66.0B

    CGEM–

  • Net income, 12 months

    ABBV$10.3B

    CGEM-$203M

  • Operating margin

    ABBV32.2%

    CGEM–

  • ROIC

    ABBV25.7%

    CGEM-46.7%

    72.4 points apart

  • P/E

    ABBV49.2

    CGEM–

  • Dividend yield

    ABBV2.4%

    CGEM0.0%

    2.4 points apart

  • 5-year return

    ABBV+194.4%

    CGEM-54.3%

    248.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+194.4%

CGEM-54.3%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsCGEMWith dividends
1 year since November 19, 2025+26.6%Price +22.9%+5.2%Price +5.2%
3 years since November 20, 2023+128.8%+31.8% a yearPrice +106.9%+1.5%+0.5% a yearPrice +1.5%
5 years since November 19, 2021+194.4%+24.1% a yearPrice +146.2%-54.3%-14.5% a yearPrice -54.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieCGEMCullinan Therapeutics

Valuation

ABBVCGEM
Valuation
Price$286.20$8.89
Market value$506B$577M
Enterprise value (EV)$576B$288M
P/E49.2–
P/E, 5-year median57.0–
P/B–2.1
EV/EBIT27.1–
Free cash flow yield3.7%–

Results and growth

ABBVCGEM
Results and growth
Revenue, 12 months$66.0B–
Net income, 12 months$10.3B-$203M
Free cash flow, 12 months$18.9B-$165M
Earnings per share, 12 months$5.81-$3.36
Revenue growth, year on year8.6%-100.0%
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVCGEM
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%–
Net margin15.7%–
ROIC25.7%-46.7%
ROE–-55.6%

Balance sheet

ABBVCGEM
Balance sheet
Cash$10.8B$290M
Total debt$80.9B$2.0M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVCGEM
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or CGEM

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Cullinan Therapeutics?

By market value, AbbVie ($506B) is about 876.8 times Cullinan Therapeutics ($577M), at today's prices.

How did ABBV and CGEM stock do over the last 5 years?

Since November 19, 2021, ABBV's price moved +146.2% and CGEM's -54.3%. With dividends: ABBV +194.4% (+24.1% a year), CGEM -54.3% (-14.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or CGEM?

The dividend yield at today's price is 2.42% for AbbVie and none for Cullinan Therapeutics. Over the last twelve months they paid $6.92 and – per share.

Which is the better investment, AbbVie or Cullinan Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.